Innovation Pharmaceuticals Inc
OTC:IPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CrowdWorks Inc
TSE:3900
|
JP |
|
Kangwon Land Inc
KRX:035250
|
KR |
|
R
|
Reyna Silver Corp
XTSX:RSLV
|
CA |
|
Technos SA
BOVESPA:TECN3
|
BR |
|
Uranium Energy Corp
XETRA:U6Z
|
US |
|
Ashland Global Holdings Inc
NYSE:ASH
|
US |
|
B
|
Beauty Farm Medical & Health Industry Inc
HKEX:2373
|
CN |
|
V
|
Volkswagen AG
OTC:VWAGY
|
DE |
|
C
|
Communications Systems Inc
XBER:VC9
|
US |
|
V
|
Volkswagen AG
SWB:VOW3
|
DE |
|
T
|
tripla Co Ltd
TSE:5136
|
JP |
|
E
|
Erato Energy SA
WSE:ERA
|
PL |
Innovation Pharmaceuticals Inc
Total Current Liabilities
Innovation Pharmaceuticals Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innovation Pharmaceuticals Inc
OTC:IPIX
|
Total Current Liabilities
$5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Current Liabilities
$641.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
37%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
Innovation Pharmaceuticals Inc
Glance View
Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The firm is engaged in developing therapies with anti-inflammatory, antibiotic, antiviral, dermatology and oncology applications. The firm owns the right to numerous drug compounds, including Brilacidin, its lead drug in a class of compounds known as defensin-mimetics and Kevetrin (thioureidobutyronitrile), which is its lead anti-cancer compound. The firm's clinical trials focused on evaluating its drug candidates, including Kevetrin for the treatment of cancers and Brilacidin for treatments of Acute Bacterial Skin and Skin Structure Infection (ABSSSI), prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative colitis. The firm is focused on developing small molecule therapies to treat diseases in the areas of inflammatory diseases, cancer, dermatology and anti-infectives.
See Also
What is Innovation Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
5m
USD
Based on the financial report for Sep 30, 2023, Innovation Pharmaceuticals Inc's Total Current Liabilities amounts to 5m USD.
What is Innovation Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-6%
Over the last year, the Total Current Liabilities growth was -2%. The average annual Total Current Liabilities growth rates for Innovation Pharmaceuticals Inc have been -9% over the past three years , -9% over the past five years , and -6% over the past ten years .
